His primary areas of study are Public economics, Economic growth, Competition, Health policy and Health technology. His biological study spans a wide range of topics, including Conceptual framework, Transparency, Politics and Economic evaluation. His Economic growth research is multidisciplinary, incorporating elements of Economic impact analysis, Medical prescription, Corporate governance and Agricultural economics.
His Competition research includes elements of Generic drug, Convergence, Reference pricing, Marketing and Industrial organization. The concepts of his Health policy study are interwoven with issues in Legislation, Pharmacy, Actuarial science, Diagnosis management and End stage renal disease. He works mostly in the field of Health technology, limiting it down to topics relating to Process and, in certain cases, Flexibility and Value theory.
Panos Kanavos mainly investigates Public economics, Health care, Health technology, Economic growth and Health economics. He has researched Public economics in several fields, including Reimbursement, Systematic review, Pharmaceutical policy, Health policy and Incentive. As a part of the same scientific family, he mostly works in the field of Reimbursement, focusing on Actuarial science and, on occasion, Orphan drug.
The various areas that Panos Kanavos examines in his Health technology study include Multiple-criteria decision analysis and Process. Health economics is a subfield of Public health that Panos Kanavos investigates. His research integrates issues of Family medicine, Sick leave, Gerontology and Economic cost in his study of Public health.
His primary scientific interests are in Health technology, Public economics, Pharmaceutical policy, Multiple-criteria decision analysis and Health care. He has included themes like Process and Economic evaluation in his Health technology study. His Public economics research is multidisciplinary, incorporating perspectives in Reimbursement, Data collection, Generic drug, Systematic review and Cost containment.
The concepts of his Pharmaceutical policy study are interwoven with issues in Competition, Best practice, International trade, Price index and China. Panos Kanavos works in the field of Health care, namely Health policy. His Health policy study is concerned with Economic growth in general.
The scientist’s investigation covers issues in Health technology, Context, Pharmaceutical policy, Public economics and Risk analysis. His Health technology study integrates concerns from other disciplines, such as Operations management, Health economics, Multiple-criteria decision analysis, Economic evaluation and Social value orientations. His Pharmaceutical policy study combines topics in areas such as Finance, Reimbursement and Price index.
His Public economics research incorporates themes from Health care and Generic drug. Panos Kanavos interconnects Cost–benefit analysis, Orphan diseases and Transparency in the investigation of issues within Risk analysis. His specific area of interest is Economic growth, where Panos Kanavos studies Health policy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The rising burden of cancer in the developing world
Annals of Oncology (2006)
Assessing the economic challenges posed by orphan drugs.
Michael F. Drummond;David A. Wilson;Panos Kanavos;Peter Ubel.
International Journal of Technology Assessment in Health Care (2007)
Encouraging the use of generic medicines: implications for transition economies.
Derek R King;Panos Kanavos.
Croatian Medical Journal (2002)
Ensuring value for money in health care: the role of health technology assessment in the European Union
Corinna Sorenson;Michael Drummond;Panos Kanavos.
Diabetes expenditure, burden of disease and management in 5 EU countries
Panos Kanavos;Stacey van den Aardweg;Willemien Schurer.
Competition in off‐Patent Drug Markets: Issues, Regulation and Evidence
Panos Kanavos;Joan Costa-Font;Elizabeth Seeley.
Economic Policy (2008)
Socio-economic burden of rare diseases: A systematic review of cost of illness evidence
Aris Angelis;David Tordrup;Panos Kanavos.
Health Policy (2015)
Early chronic kidney disease: diagnosis, management and models of care
Olivier J. Wouters;Donal J. O'Donoghue;James Ritchie;Panos G. Kanavos.
Nature Reviews Nephrology (2015)
Centralized Drug Review Processes In Australia, Canada, New Zealand, And The United Kingdom
Steven G. Morgan;Meghan McMahon;Craig Mitton;Elizabeth Roughead.
Health Affairs (2006)
Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden.
Alessandra Ferrario;Panos Kanavos.
Social Science & Medicine (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: